Related Experiment Video
Updated: Sep 28, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
The silent storm: Quinine-induced Torsade de Pointes unmasking a latent KCNH2 variant
Humberto Morais1, Miguel Vicente2, Catarina David3
1Hospital Militar Principal/Instituto Superior.
Abstract:
Quinine, a Cinchona alkaloid and a cornerstone of malaria therapy in resource-limited settings, produces predominant sodium-channel blockade alongside modest inhibition of the rapid delayed-rectifier potassium current (IKr). Although generally safe at the population level, even modest IKr blockade can precipitate life-threatening Torsade de Pointes (TdP) in patients with severely impaired repolarization reserve. We report an 8-year-old boy with severe Plasmodium falciparum malaria who, on the third day of intravenous quinine, developed profound QTc prolongation (730 ms) followed by recurrent TdP. This arose from the convergence of quinine-induced IKr inhibition, hypokalaemia (K 2.9 mmol/L), and an underlying pathogenic KCNH2 variant, which together exhausted repolarization reserve. Although initially haemodynamically stable, the patient's extreme electrical instability proved a sentinel event, prompting identification of latent Long QT Syndrome type 2 (LQT2). The case highlights the importance of ECG monitoring and electrolyte correction during quinine therapy. It illustrates how drug-induced arrhythmia can represent the phenotypic unmasking of diminished repolarization reserve, in which a pharmacological trigger exposes a silent genetic substrate-here necessitating lifelong beta-blocker therapy and family cascade screening to prevent sudden cardiac death.
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antihypertensive Drugs: Potassium-Sparing Diuretics

